Cloning and mutagenesis market seen reaching $8.5B by 2030

A new Business Research Company report says the cloning and mutagenesis market will grow from $3.54 billion in 2025 to $8.5 billion by 2030, driven by personalized medicine, synthetic biology and automated lab tools. North America led the market in 2025, while Asia-Pacific is expected to grow fastest through the forecast period.

Why it matters: - Cloning and mutagenesis are core tools for gene function analysis, disease modeling, drug discovery and recombinant protein production. - The market tied to those techniques is expanding as biotech and therapeutic development lean more heavily on precision genome editing. - Personalized medicine is increasing demand for the technologies because treatments are being tailored to patient genetics.

What happened: - The Business Research Company published its Cloning And Mutagenesis Market Report 2026, covering market size, trends and global forecasts for 2026-2035. - The report puts the market at $3.54 billion in 2025 and $4.21 billion in 2026. - The report forecasts the market will reach $8.5 billion by 2030. - The report pegs the forecast-period CAGR at 19.2%. - The company released a free sample of the report and a full report.

The details: - Historical growth has been supported by more funding for academic research, advances in recombinant protein studies, wider use of genetic engineering tools, broader access to standardized molecular biology kits and more biotech startups. - Future growth is expected to come from higher demand for gene function analysis, broader use of synthetic biology, more investment in therapeutic protein development, adoption of automated laboratory platforms and stronger focus on precision genome editing. - Cloning and mutagenesis involve making multiple copies of DNA, genes or genomes and introducing specific mutations into DNA sequences. - These methods are used to study gene function and regulatory mechanisms and to develop drugs, therapeutic agents, recombinant enzymes and proteins. - Personalized medicine is a major growth driver because cloning and mutagenesis support disease modeling, drug discovery, gene therapy, target identification, biomarker research, patient-specific cell therapies, pharmacogenomics and genome editing. - The Personalized Medicine Coalition reported that the FDA approved 16 new personalized therapies for rare diseases in 2023, up from 6 in 2022. - North America held the largest share of the market in 2025. - Asia-Pacific is projected to be the fastest-growing region across the forecast period. - The report also covers South East Asia, Western Europe, Eastern Europe, South America and the Middle East and Africa.

Between the lines: - The forecast points to a research market shifting from basic lab use toward clinical and industrial applications. - The personalized medicine data shows how regulatory approval trends can feed demand for enabling technologies. - The regional outlook suggests mature demand in North America and faster adoption in Asia-Pacific as biotech investment broadens. - The report’s added features, including TAM analysis, company scoring matrices, dashboards and hotspot infographics, are designed to help buyers compare opportunities faster.

What's next: - Demand will likely rise as more drug programs, cell therapies and genome-editing projects move through development. - Automated lab systems and updated molecular biology workflows should keep improving throughput and reproducibility. - Regional competition is likely to intensify as Asia-Pacific closes the gap on North American market leadership.

The bottom line: - Cloning and mutagenesis is moving from a specialist research category into a broader platform market tied to precision medicine and synthetic biology.